Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

US9701639B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Mark Strohmeier · Arlington, US
• John P. Caesar, Jr. · Lancaster, US
• Patrick R. Connelly · Harvard, US
• Majed Fawaz · Foxborough, US
• Eduard Luss-Lusis · Arlington, US
• Brian McClain · Harvard, US
• Ales Medek · Winchester, US
• Hai Miao · Winchester, US
• Kwame Wiredu Nti-Addae · Tewksbury, US
• Ping Yin · Boston, US
• Yuegang Zhang · Wayland, US

Key dates

• Filing date: Oct 7, 2015
• Grant date: Jul 11, 2017
• Expiry date: Oct 7, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.